Close Menu

NEW YORK – Diagnostic firm SpeeDx announced Tuesday a partnership with Roche to expand global access to the firm's infectious disease and antibiotic resistance tests and technology.

Under the non-exclusive agreement, Roche will have access to SpeeDx's existing tests and technology, expanding patient access to diagnostic products, including new ones, for the management of antibiotic resistance in sexually transmitted infections, the firm said in a statement.

Financial and other terms of the deal were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.